Table 1.

Blood vessel density in CML patients treated with imatinib

Initial biopsy
3 months
6 months
12 months
Patient no.
Disease phase
Ph positive (%)
Vessels (mean)
Ph positive (%)
Vessels (mean)
Vessels (% control)
Ph positive (%)
Vessels (mean)
Vessels (% control)
Ph positive (%)
Vessels (mean)
Vessels (% control)
1   CP1, newly diagnosed   100   50   69   ND   ND   63   11   22   ND   ND   ND  
2   CP1, newly diagnosed   100   74   16   ND   ND   0   9   12   0   ND   ND  
3   CP1, newly diagnosed   100   2   28   ND   ND   4   5   250   0   0   0.00  
4   CP1, newly diagnosed   100   9   0   ND   ND   0   5   56   0   ND   ND  
5   CP1, newly diagnosed   100   5   ND   ND   ND   0   1   20   0   6   1.20  
6   CP1, newly diagnosed   100   9   0   5   56   32   4   44   0   ND   ND  
7   CP1, newly diagnosed   100   14   9   19   36   2   9   64   0   ND   ND  
8   CP1, newly diagnosed   100   21   100   5   24   60   3   14   68   ND   ND  
9   CP1, newly diagnosed   100   24   ND   8   33   16   2   8   0   11   0.46  
10   CP1, newly diagnosed   100   40   4   ND   ND   0   ND   ND   0   ND   ND  
11   CP1, newly diagnosed   100   13   52   10   77   84   5   38   28   ND   ND  
12   CP1, newly diagnosed   100   11   25   11   100   4   ND   ND   0   ND   ND  
13   CP1, IFN intolerance   100   41   100   7   17   98   4   10   100   8   0.20  
14   CP1, IFN intolerance   88   1   6   2   200   0   0   0   0   1   1.00  
15   CP1, IFN intolerance   50   18   0   14   78   3(IP-F)   13   72   ND   9   0.50  
16   CP1, IFN intolerance   96   3   96   1   33   68   2   67   100   ND   ND  
17   CP1, IFN cytogenetic resistance   100   18   60   7   39   8   1   6   ND   ND   ND  
18   CP1, IFN cytogenetic resistance   100   2   96   2   100   100   3   150   68   1   0.50  
     40          
 		 Median (range) of all
 		 100 (50-100)
 		 13 (1-74)
 		 (0-100)
 		 7 (1-19)
 		 56 (17-200)
 		 3 (0-100)
 		 4 (0-13)
 		 22 (0-250)
 		 0 (0-100)
 		 *
 		 *
 
Initial biopsy
3 months
6 months
12 months
Patient no.
Disease phase
Ph positive (%)
Vessels (mean)
Ph positive (%)
Vessels (mean)
Vessels (% control)
Ph positive (%)
Vessels (mean)
Vessels (% control)
Ph positive (%)
Vessels (mean)
Vessels (% control)
1   CP1, newly diagnosed   100   50   69   ND   ND   63   11   22   ND   ND   ND  
2   CP1, newly diagnosed   100   74   16   ND   ND   0   9   12   0   ND   ND  
3   CP1, newly diagnosed   100   2   28   ND   ND   4   5   250   0   0   0.00  
4   CP1, newly diagnosed   100   9   0   ND   ND   0   5   56   0   ND   ND  
5   CP1, newly diagnosed   100   5   ND   ND   ND   0   1   20   0   6   1.20  
6   CP1, newly diagnosed   100   9   0   5   56   32   4   44   0   ND   ND  
7   CP1, newly diagnosed   100   14   9   19   36   2   9   64   0   ND   ND  
8   CP1, newly diagnosed   100   21   100   5   24   60   3   14   68   ND   ND  
9   CP1, newly diagnosed   100   24   ND   8   33   16   2   8   0   11   0.46  
10   CP1, newly diagnosed   100   40   4   ND   ND   0   ND   ND   0   ND   ND  
11   CP1, newly diagnosed   100   13   52   10   77   84   5   38   28   ND   ND  
12   CP1, newly diagnosed   100   11   25   11   100   4   ND   ND   0   ND   ND  
13   CP1, IFN intolerance   100   41   100   7   17   98   4   10   100   8   0.20  
14   CP1, IFN intolerance   88   1   6   2   200   0   0   0   0   1   1.00  
15   CP1, IFN intolerance   50   18   0   14   78   3(IP-F)   13   72   ND   9   0.50  
16   CP1, IFN intolerance   96   3   96   1   33   68   2   67   100   ND   ND  
17   CP1, IFN cytogenetic resistance   100   18   60   7   39   8   1   6   ND   ND   ND  
18   CP1, IFN cytogenetic resistance   100   2   96   2   100   100   3   150   68   1   0.50  
     40          
 		 Median (range) of all
 		 100 (50-100)
 		 13 (1-74)
 		 (0-100)
 		 7 (1-19)
 		 56 (17-200)
 		 3 (0-100)
 		 4 (0-13)
 		 22 (0-250)
 		 0 (0-100)
 		 *
 		 *
 

ND indicates not determined; IP-F, *

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal